AIM Vaccine (AIM Vaccine Co., Ltd.) has published its fourth Environmental, Social and Governance (ESG) Report, detailing 2025 operating performance, governance enhancements, R&D progress and climate-related targets.

Financial & R&D Highlights • Full-year operating revenue reached RMB 1.17 billion, according to the ESG data tables. • R&D expenditure totalled RMB 356.09 million, representing 30.55% of revenue. The group managed 20 vaccine projects across 12 disease areas and held 189 active patents after filing 14 new applications and securing 31 grants during the year.

Governance & Compliance • The nine-member board (five executive, one non-executive, three independent) oversaw six board meetings and adopted a three-tier ESG governance structure. • Zero cases of corruption, unfair-competition litigation or regulatory penalties were recorded. All directors and employees (100%) completed anti-corruption training.

Environmental Performance • Comprehensive energy consumption was 16,639.64 tce, while Scope 1 and Scope 2 greenhouse-gas emissions totalled 53,168 tCO₂e, equating to 0.46 tCO₂e per RMB 10,000 of revenue. • A 5% reduction in emissions intensity by 2030 has been pledged by subsidiary AIM Honesty, alongside renewable-energy adoption—2,380 MWh of solar power was generated at AIM Action. • Wastewater, exhaust-gas and noise emissions all achieved 100% compliance; no environmental penalties were imposed.

Social Metrics • The workforce stood at 1,466 employees (49% female). Staff turnover was 12.07%; no child or forced labour cases occurred. • Training coverage reached 86.77%, with an average 30.26 training hours per employee. • Workplace safety recorded zero fatalities; 127.88 workdays were lost to injuries. • Community investment amounted to RMB 6.03 million, including hepatitis-related testing reagent and vaccine donations.

Product Quality & Safety • Four production subsidiaries passed national GMP inspections; 230 vaccine batches were tested with a 100% in-house pass rate and 100% lot-release approval. • No product recalls or customer-complaint cases occurred during the year.

Looking Forward AIM Vaccine reiterated its commitment to expand green energy use, deepen R&D across its five technology platforms and pursue international market registration for key vaccines such as its 13-valent pneumococcal conjugate candidate.